Australia’s Therapeutic Goods Administration has suspended from the market 23 ranitidine drugs after testing found the products contained “unacceptable” levels of potential carcinogen N-nitrosodimethylamine (NDMA).
All 23 products have been given a six-month suspension from the Australian Register of Therapeutic Goods (ARTG), which will
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on HBW Insight for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?